Cohort profile: Nordic Helicobacter Pylori eradication project (NordHePEP) ...

• Main Authors: Pettersson, Anna-Klara, Santoni, Giola, Yan, Jacinth, Radkiewicz, Cecilia, Xie, Shaohua, Birgisson, Helgi, Ness-Jensen, Eivind, von Euler-Chelpin, My, Kauppila, Joonas H., Lagergren, Jesper
• Format: Text
• Language: unknown
• Published: Taylor & Francis 2022
• Subjects: Medicine; Cell Biology; Pharmacology; Biotechnology; 39999 Chemical Sciences not elsewhere classified; FOS Chemical sciences; Ecology; FOS Biological sciences; Immunology; FOS Clinical medicine; Cancer; 110309 Infectious Diseases; FOS Health sciences; 60506 Virology; Computational Biology; Norway; Iceland
• Online Access: https://dx.doi.org/10.6084/m9.figshare.21545800; https://tandf.figshare.com/articles/journal_contribution/Cohort_profile_Nordic_Helicobacter_Pylori_eradication_project_NordHePEP_/21545800

This cohort description presents the Nordic Helicobacter Pylori Eradication Project (NordHePEP), a population-based cohort of patients having received eradication treatment for Helicobacter pylori (HP). The cohort is created with the main purpose of examining whether and to what extent HP eradication treatment influences the risk of gastrointestinal cancer. NordHePEP includes all adults (aged ≥18 years) having been prescribed and dispensed HP eradication treatment according to the nationwide complete drug registries in any of the five Nordic countries (Denmark, Finland, Iceland, Norway, or Sweden) between 1994 and 2020 (start and end year varies between countries). We have retrieved and merged individual-level data from multiple national registries, including drug, patient, cancer, population, and death registries. The cohort includes 674,771 patients having received HP eradication treatment. During up to 23 years of follow-up, 59,292 (8.8%) participants were diagnosed with cancer (non-melanoma skin cancer ...